Intercept Pharma Begins Phase 2 NASH Trial of OCA in Japan

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Intercept Pharmaceuticals, Inc.(Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focusedon the development and commercialization of novel bile acid therapeutics totreat chronic liver diseases, today announced that its partner DainipponSumitomo Pharma (DSP) has initiated a phase 2 clinical trial of obeticholicacid (OCA) in adult nonalcoholic steatohepatitis (NASH) patients in Japan.The trial is studying the efficacy and safety of a once daily dose of OCA,with the goal of randomizing 200 NASH patients to receiving OCA or placebo.The primary endpoint will be evaluated by histological improvement. DSPexpects to complete the trial in the first half of 2016.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!